In the glioma TIME, NK cells have emerged as promising therapeutic effectors against GBM heterogeneity, attributable to their nonspecific cytolysis activities and their role in orchestrating tumor immune responses by releasing a spectrum of cytokines.[46] Building on evidence suggesting that NK cells may target cancer stem cells,[47] a coculture system of GSCs and NK‐92 cells was established to investigate the immunomodulatory effects of B7 in the glioma TIME. The gene discussed is CD80; the disease is cancer.